Replies to post #98301 on Biotech Values

[DewDiligence]

…the Mayo Clinic has challenging the validity of two Prometheus patents based upon suspect patentable subject matter (U.S. Patents 6,355,623 and 6,680,302). The Prometheus patents claim an iterative approach to dosing that involves three steps: (1) first administer a drug to a subject; (2) then determine the level of drug in the subject; and (3) finally decide whether the next dose should be the same, higher, or lower. The decision on the next dose is made by comparing the the level of the drug in the subject against predetermined thresholds.

It’s dismaying that a court deemed an “invention” like this sufficiently non-obvious to be patentable. I would like to see the lower court reverse its original ruling following the remand.